Failure of stop and go in de novo Parkinson's disease-a functional magnetic resonance imaging study

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 470-475

  Vriend, Chris ^a,b   Gerrits, Niels J H M ^a,b   Berendse, Henk W ^a,b   Veltman, Dick J ^a,b   van den Heuvel, Odile A ^a,b   van der Werf, Ysbrand D ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Dopamine transporter; Functional MRI; Impulse control disorders; Parkinson's disease; Response inhibition

Indexed keywords

IOFLUPANE I 123; DOPAMINE TRANSPORTER;

AGED; ARTICLE; BEHAVIORAL SCIENCE; BOLD SIGNAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL DISEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMPULSE CONTROL DISORDER; INFERIOR FRONTAL GYRUS; MALE; MENTAL TASK; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PARKINSON DISEASE; PSYCHOLOGIC TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; INHIBITION (PSYCHOLOGY); MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX;

AGED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PREFRONTAL CORTEX; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX;

EID: 84920555323     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.031     Document Type: Article

References (44)

1. Aarts E., Helmich R.C., Janssen M.J., Oyen W.J., Bloem B.R., Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. Neuroimage 2012, 59:3339-3346.
2. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
3. Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Association, American Psychiatric Publishing, Arlington, VA. fifth ed.
4. Aron A.R. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol. Psychiatry 2011, 69:e55-68.
5. Baglio F., Blasi V., Falini A., Farina E., Mantovani F., Olivotto F., Scotti G., Nemni R., Bozzali M. Functional brain changes in early Parkinson's disease during motor response and motor inhibition. Neurobiol. Aging 2011, 32:115-124.
6. Bari A., Robbins T.W. Inhibition and impulsivity: behavioral and neural basis of response control. Prog. Neurobiol. 2013, 108:44-79.
7. Beste C., Baune B.T., Domschke K., Falkenstein M., Konrad C. Paradoxical association of the brain-derived-neurotrophic-factor val66met genotype with response inhibition. Neuroscience 2010, 166:178-184.
8. Beste C., Dziobek I., Hielscher H., Willemssen R., Falkenstein M. Effects of stimulus-response compatibility on inhibitory processes in Parkinson's disease. Eur. J. Neurosci. 2009, 29:855-860.
9. Blalock H.M. Correlated independent variables: the problem of multicollinearity. Social Forces 1963, 42:233-237.
10. Bokura H., Yamaguchi S., Kobayashi S. Event-related potentials for response inhibition in Parkinson's disease. Neuropsychologia 2005, 43:967-975.
11. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
12. Cilia R., Ko J.H., Cho S.S., van Eimeren T., Marotta G., Pellecchia G., Pezzoli G., Antonini A., Strafella A.P. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol. Dis. 2010, 39:98-104.
13. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. 2011, 12:359-366.
14. Congdon E., Mumford J.A., Cohen J.R., Galvan A., Canli T., Poldrack R.A. Measurement and reliability of response inhibition. Front. Psychol. 2012, 3:37.
15. Cramer D. Acautionary tale of two statistics: partial correlation and standardized partial regression. J.Psychol. 2003, 137:507-511.
16. Dalley J.W., Roiser J.P. Dopamine, serotonin and impulsivity. Neuroscience 2012, 215:42-58.
17. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J. Neural Transm. 1993, 39:165-172.
18. de Wit S.J., de Vries F.E., van der Werf Y.D., Cath D.C., Heslenfeld D.J., Veltman E.M., van Balkom A.J., Veltman D.J., van den Heuvel O.A. Presupplementary motor area hyperactivity during response inhibition: a candidate endophenotype of obsessive-compulsive disorder. Am. J. Psychiatry 2012, 169:1100-1108.
19. Fahn S., Elton R.L. Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, 153-163. and members of the UPDRS Development Committee, Macmillan Healthcare Information, Florham Park, NJ. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
20. Farid K., Sibon I., Guehl D., Cuny E., Burbaud P., Allard M. Brain dopaminergic modulation associated with executive function in Parkinson's disease. Mov. Disord. 2009, 24:1962-1969.
21. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I/P). Biometrics Research Department 2002, New York State Psychiatric Institute, NewYork.
22. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J.Psychiatr. Res. 1975, 12:189-198.
23. Gauggel S., Rieger M., Feghoff T.A. Inhibition of ongoing responses in patients with Parkinson's disease. J.Neurol. Neurosurg. Psychiatry 2004, 75:539-544.
24. Hesse S., Meyer P.M., Strecker K., Barthel H., Wegner F., Oehlwein C., Isaias I.U., Schwarz J., Sabri O. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:428-435.
25. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
26. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N.Engl. J. Med. 1988, 318:876-880.
27. Lee J.Y., Seo S.H., Kim Y.K., Yoo H.B., Kim Y.E., Song I.C., Lee J.S., Jeon B.S. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J.Neurol. Neurosurg. Psychiatry 2013, 85:23-30.
28. Nombela C., Rittman T., Robbins T.W., Rowe J.B. Multiple Modes of impulsivity in Parkinson's disease. PLoS one 2014, 9:e85747.
29. Obeso I., Wilkinson L., Casabona E., Bringas M.L., Alvarez M., Alvarez L., Pavon N., Rodriguez-Oroz M.C., Macias R., Obeso J.A., Jahanshahi M. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp. Brain Res. 2011, 212:371-384.
30. Obeso I., Wilkinson L., Jahanshahi M. Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. Exp. Brain Res. 2011, 213:435-445.
31. O'Callaghan C., Naismith S.L., Hodges J.R., Lewis S.J., Hornberger M. Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. Cortex 2013, 49:1833-1843.
32. Reuter-Lorenz P.A., Lustig C. Brain aging: reorganizing discoveries about the aging mind. Curr. Opin. Neurobiol. 2005, 15:245-251.
33. Schmand B., Bakker D., Saan R., Louman J. [The Dutch Reading Test for Adults: a measure of premorbid intelligence level]. Tijdschr. Gerontol. Geriatr. 1991, 22:15-19.
34. Sebastian A., Baldermann C., Feige B., Katzev M., Scheller E., Hellwig B., Lieb K., Weiller C., Tuscher O., Kloppel S. Differential effects of age on subcomponents of response inhibition. Neurobiol. Aging 2013, 34:2183-2193.
35. van der Vegt J.P., Hulme O.J., Zittel S., Madsen K.H., Weiss M.M., Buhmann C., Bloem B.R., Munchau A., Siebner H.R. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease. Brain 2013, 136(Pt 4):1192-1203.
36. van Velzen L.S., Vriend C., de Wit S.J., van den Heuvel O.A. Response inhibition and interference control in obsessive-compulsive spectrum disorders. Front. Hum. Neurosci. 2014, 8:419.
37. Varrone A., Dickson J.C., Tossici-Bolt L., Sera T., Asenbaum S., Booij J., Kapucu O.L., Kluge A., Knudsen G.M., Koulibaly P.M., Nobili F., Pagani M., Sabri O., Vander Borght T., Van Laere K., Tatsch K. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur. J. Nucl. Med. Mol. Imaging 2013, 40:213-227.
38. Verbruggen F., Chambers C.D., Logan G.D. Fictitious inhibitory differences how skewness and slowing distort the estimation of stopping latencies. Psychol. Sci. 2013, 24:352-362.
39. Voon V., Rizos A., Chakravartty R., Mulholland N., Robinson S., Howell N.A., Harrison N., Vivian G., Ray Chaudhuri K. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J.Neurol. Neurosurg. Psychiatry 2013, 85:148-152.
40. Vriend C., Nordbeck A.H., Booij J., Van der Werf Y.D., Pattij T., Voorn P., Raijmakers P., Foncke E.M.J., van de Giessen E., Berendse H.W., Van den Heuvel O.A. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov. Disord. 2014, 29:904-911.
41. Vriend C., Pattij T., van der Werf Y.D., Voorn P., Booij J., Rutten S., Berendse H.W., van den Heuvel O.A. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?. Neurosci. Biobehav. Rev. 2014, 38:60-71.
42. Vriend C., Raijmakers P., Veltman D.J., van Dijk K.D., van der Werf Y.D., Foncke E.M., Smit J.H., Berendse H.W., van den Heuvel O.A. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J.Neurol. Neurosurg. Psychiatry 2014, 85:159-164.
43. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Whetteckey J., Wunderlich G.R., Lang A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67:589-595.
44. Ye Z., Altena E., Nombela C., Housden C.R., Maxwell H., Rittman T., Huddleston C., Rae C.L., Regenthal R., Sahakian B.J., Barker R.A., Robbins T.W., Rowe J.B. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014, 137(Pt 4):1145-1155.